Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid
Samia Ragheb1, Yanfeng Li, Kirk Simon
1Department of Neurology, Wayne State University, Detroit, MI 48201, USA. sragheb@med.wayne.edu
Multiple Sclerosis (Houndmills, Basingstoke, England)
|March 5, 2011
Summary
Levels of B-cell activating factor (BAFF) and CXCL13 are elevated in multiple sclerosis (MS) patients, particularly during relapse. These B-cell-related molecules may contribute to MS pathogenesis by influencing B-cell activity.
Area of Science:
- Neuroimmunology
- Autoimmune diseases
- Biomarker research
Background:
- B-cell involvement is increasingly implicated in multiple sclerosis (MS) pathogenesis.
- B-cell activating factor (BAFF) is crucial for B-cell survival and homeostasis.
- CXCL13, a chemokine, plays a key role in B-cell follicle formation and maintenance.
Purpose of the Study:
- To quantify BAFF and CXCL13 levels in cerebrospinal fluid (CSF) of MS patients.
- To compare these levels with those in patients suffering from other neurological diseases.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was employed to measure cytokine and chemokine concentrations.
- Cerebrospinal fluid (CSF) samples from MS patients and controls were analyzed.
Main Results:
- BAFF levels were highest in secondary progressive MS and elevated during relapse in relapsing-remitting and secondary progressive MS.
- CXCL13 levels were also elevated during relapse in MS patients.
- A positive correlation was observed between CXCL13 and the IgG index, while BAFF showed an inverse correlation with the IgG index.
Conclusions:
- Elevated BAFF and CXCL13 during relapse suggest their concerted action in MS.
- These molecules, vital for B-cell functions, may collectively impact B-cell homeostasis and contribute to MS pathophysiology.
- Further research into these B-cell-related factors could reveal new therapeutic targets for MS.
